Permeon™ Biologics Announces the Appointment of Katherine S. Bowdish, Ph.D., as President and Chief Scientific Officer

February 24, 2012

Successful Entrepreneur and Industry Veteran Joins Company to Continue to Advance Breakthrough Intraphilin Technology Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the appointment of Katherine S. Bowdish, Ph.D., as president and chief scientific officer. Dr. Bowdish also joins the Permeon board of directors. Previously, Dr. Bowdish was the co-founder, president and chief executive officer of Anaphore, a platform-based drug development company pioneering Atrimers, a new class of trivalent protein pharmaceuticals. Before founding Anaphore, she founded Prolifaron, a leading innovator of antibody technologies that grew through large pharma partnerships and ultimately merged with Alexion Pharmaceuticals. Following that merger, Dr. Bowdish served as president of Alexion Antibody Technologies, Inc. and senior vice president antibody discovery of Alexion Pharmaceuticals.

“We are pleased to welcome Kathy to the Permeon team. Her proven expertise and success in leading and building innovative biotechnology companies are invaluable to Permeon as we continue to advance our novel Intraphilin Technology Platform,” said John Edwards, executive chairman of Permeon. “We would also like to thank Dr. Alex Franzusoff for his contributions to the company and his work in positioning Permeon at the forefront of the development of this breakthrough class of intracellular biologics.”

“This is an exciting time for Permeon and for our industry as we are poised to realize a true breakthrough in intracellular protein biologics,” said Dr. Bowdish. “Our approach enables us to discover and develop an entirely new class of naturally occurring human supercharged proteins and address a broad spectrum of previously undruggable targets. I look forward to working with the Permeon team as we make important progress this year, further developing our technology and advancing our programs.”

Earlier in her career, Dr. Bowdish was a research biologist at Monsanto where she created the first insect-tolerant transgenic plants, and worked with Richard A. Lerner, M.D., at The Scripps Research Institute on catalytic antibodies and antibody repertoire cloning. Dr. Bowdish earned her B.S. in Biology at the College of William and Mary and her Ph.D. in the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University College of Physicians and Surgeons. She is the author or co-author of more than 26 peer-reviewed scientific publications and is the inventor on 13 issued U.S. patents and multiple patents pending.

About the Intraphilin™ Technology Platform

Many of today’s blockbuster drugs are protein-based biologics that work outside of cells either as replacement enzymes or by binding to extracellular targets to treat disease. The size and electrical charge of protein biologics normally prevent them from penetrating cell membranes to function inside the cell, limiting the therapeutic utility of this class of drugs. The Intraphilin™ Technology Platform has the potential to enable human biologic drugs to function inside of cells and treat disease.

About Permeon Biologics

Permeon Biologics is pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Leveraging its Intraphilin Technology Platform exclusively licensed from Harvard University, the company’s next-generation approach is being developed to unlock the full therapeutic potential of current blockbuster technologies for human biologics. The Intraphilin™ Technology Platform enables protein-based therapeutics to act inside cells to treat disease, opening access to more than 1,500 intracellular targets that are deemed undruggable by existing technologies. Based in Cambridge, Mass., Permeon Biologics is backed by marquee investors, Flagship Ventures and ARCH Venture Partners, and is led by a world-class scientific advisory board and proven management team. For more information, visit www.permeonbio.com. Permeon and Intraphilin are trademarks of Permeon Biologics, Inc.

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.